
Biotech/Pharma



CRISPNA, a new tool for genoma editing and diagnosis

A research group from the Andalusian Public Health System (SSPA) has developed CRISPNA, a new tool for genome editing and disease diagnosis. This tool is versatile, robust, stable and specific.

Oficina de TRANSFERENCIA DE TECNOLOGÍA Sistema Sanitario Público de Andalucía





CRISPR/Cas systems are powerful technologies that are changing the way scientists tackle unsolved problems in basic biology, therapy and diagnosis. In its present forms, the different CRISPR/Cas systems require RNA molecules (crRNAs or sgRNAs) to direct the different Cas proteins to their DNA or RNA targets. These crRNAs or sgRNAs are potent and specific but unstable molecules.

This new tool instead uses peptide nucleic acids (PNAs), artificial synthetic oligonucleotides that display higher affinity for complementary DNA and RNA than do normal oligonucleotides.



This invention combines the versatility of CRISPR-associated enzymes (Cas) with the robustness, stability and specificity of peptide nucleic acids (PNAs) to generate CRISPNA technology, with improved characteristics over CRISPR systems.



The technology is protected by a PCT patent application



The research group is looking for a collaboration agreement for further development or a licence agreement.



Category: Biotech/Pharma (Therapy) Technology: Cell Therapy Pathology: blood and lymphatic system



CENTRO PFIZER-UNIVERSIDAD DE GRANA JUNTA DE ANDALICA DE GENÓMICA E INVESTIGACIÓN OROCIÓGICA

Avda. Américo Vespucio 5, bloque 2, 2ª Plta. Parque Científico y Tecnológico de la Cartuja 41092 Sevilla 🕾 +34 954 712 376 MÓVIL +34 671 597 655 **Thelena.maldonado@juntadeandalucia.es**